Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
Authors:
- Mattia GaruttiMattia Garutti
- Gaia GriguoloGGGaia Griguolo
- Andrea BotticelliABAndrea Botticelli
- Giulia BuzzattiGBGiulia Buzzatti
- Carmine De AngelisCarmine De Angelis
- Lorenzo GerratanaLGLorenzo Gerratana
- Chiara MolinelliCMChiara Molinelli
- Vincenzo AdamoVAVincenzo Adamo
- Giampaolo BianchiniGBGiampaolo Bianchini
- Laura BiganzoliLaura Biganzoli
- Giuseppe CuriglianoGCGiuseppe Curigliano
- Michelino De LaurentiisMLMichelino De Laurentiis
Open Access
Abstract
Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.Keywords
This publication has 86 references indexed in Scilit:
- Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast CancerJNCI: Journal of the National Cancer Institute, 2013
- EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerAnnals of Oncology, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialAnnals of Oncology, 2011
- Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapyBritish Journal of Cancer, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991